ASND vs INCY

For growth investors, Ascendis Pharma A/S (ASND) is the stronger pick with 90.

2% revenue growth year-over-year, versus 21. 2% for Incyte Corporation (INCY). Incyte Corporation (INCY) offers the better valuation at 15. 3x trailing P/E (13. 1x forward), making it the more compelling value choice. Analysts rate Ascendis Pharma A/S (ASND) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Incyte Corporation is actually cheaper at 13.

1x.

Over the past 5 years, Ascendis Pharma A/S (ASND) delivered a total return of +85.

2%, compared to +18. 2% for Incyte Corporation (INCY). Over 10 years, the gap is even starker: ASND returned +1451% versus INCY's +34. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ascendis Pharma A/S (ASND) is the lower-risk stock at 0.

33β versus Incyte Corporation's 0. 87β — meaning INCY is approximately 165% more volatile than ASND relative to the S&P 500.

By revenue growth (latest reported year), Ascendis Pharma A/S (ASND) is pulling ahead at 90.

2% versus 21. 2% for Incyte Corporation (INCY). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to 44. 6% for Ascendis Pharma A/S. Over a 3-year CAGR, ASND leads at 138. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Incyte Corporation (INCY) is the more profitable company, earning 25.

0% net margin versus -31. 7% for Ascendis Pharma A/S — meaning it keeps 25. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INCY leads at 26. 1% versus -18. 9% for ASND. At the gross margin level — before operating expenses — INCY leads at 91. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Incyte Corporation (INCY) trades at 13.

1x forward P/E versus 61. 8x for Ascendis Pharma A/S — 48. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ASND: 16. 7% to $287. 17.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ascendis Pharma A/S (ASND) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

33), +1451% 10Y return). Both have compounded well over 10 years (ASND: +1451%, INCY: +34. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.